News
08/13/2021
Virginia Bio to partner with Mason Enterprise to expand mentorship support for bio startups across the state
George Mason University’s Mason Enterprise is establishing a new network of life science business mentors to help startups across Virginia launch and scale their ventures. The new team of mentors will support a broad range of life science companies in bringing their innovations, including therapeutics, medical devices, diagnostics and software, to market. This network will …
08/12/2021
FDA Solicits Feedback on Drug Products Approved Under Abbreviated New Drug Applications Before the Enactment of the Hatch-Waxman Amendments
The FDA has established a public docket to solicit comments on several issues related to FDA’s regulation of certain drug products approved under abbreviated new drug applications before the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. Because these Pre-Hatch-Waxman ANDAs (PANDAs) were submitted under …
08/04/2021
Allulose Patents Granted to Bonumose for Unique Enzymatic Conversion Process
Bonumose is pleased to announce that the U.S. Patent & Trademark Office has issued U.S. Patent No. 11,078,506 for “Enzymatic Production of D-Allulose”. This patent issuance follows Bonumose’s Allulose U.S. Patent No. 11,053,528 (July 6, 2021) and allulose U.S. Patent No. 10,704,069 (July 7, 2020). Bonumose has been issued additional Allulose patents and/or has patent …
08/04/2021
Embody Announces $20.5M Funding Round
Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it has secured $11.5 million in an oversubscribed equity financing and entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $9 million in term loans, of which an initial $5 million has been funded, …
07/22/2021
First Two Patients Dosed in HemoShear Therapeutics Phase 2 Study
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, dosed the first two patience in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, an oral small molecule drug being investigated for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA). This trial seeks to …
07/19/2021
Phlow Corp. Receives HHS Small Business Prime Contractor of the Year Award
The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during …